<DOC>
	<DOCNO>NCT02685020</DOCNO>
	<brief_summary>The primary purpose study assess safety , tolerability different vaccine schedule ( different regimen duration different number dose administration ) Ad26.Mos.HIV Clade C Glycoprotein ( gp ) 140 assess Envelope ( Env ) -binding Antibody ( Ab ) responses different vaccine schedule .</brief_summary>
	<brief_title>Safety , Tolerability Immunogenicity Study Different Vaccine Schedules With Ad26.Mos.HIV Clade C Glycoprotein ( gp ) 140 Healthy Human Immunodeficiency Virus ( HIV ) -Uninfected Adults</brief_title>
	<detailed_description>This phase 1 single-center , randomize ( study drug assign chance ) , parallel group ( group participant treat time ) , placebo-controlled ( study experimental treatment procedure compare pretend treatment drug test drug real effect ) , double-blind ( neither physician participant know treatment participant receives ) study . Participants randomize 3 group receive study vaccine placebo . Group 1 4 vaccination time point 48 week , Groups 2 3 3 vaccination time point 24 week . The study comprise Screening Period ( 4 week ) , Vaccination Period ( maximum 48 week ) , Follow-up Period ( 72 week ) . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<mesh_term>Aluminum phosphate</mesh_term>
	<criteria>Each participant must sign informed consent form ( ICF ) indicate understands purpose procedure require study voluntarily willing participate study Participant must healthy basis physical examination , medical history , electrocardiogram ( ECG ) , vital sign measurement perform Screening Participants negative Human Immunodeficiency Virus ( HIV ) infection Screening All female participant childbearing potential must negative serum pregnancy test ( beta human chorionic gonadotropin [ beta hCG ] ) Screening visit , negative urine pregnancy test predose Day 1 Participants willing/able adhere prohibition restriction specify protocol study procedure Participant chronic hepatitis B active hepatitis C , active syphilis infection , chlamydia , gonorrhea , trichomonas . Active syphilis document serology unless positive serology due past treated infection In 12 month prior randomization , participant history newly acquire herpes simplex virus type 2 , syphilis , gonorrhea , nongonococcal urethritis , chlamydia , pelvic inflammatory disease , trichomonas , mucopurulent cervicitis , epididymitis , proctitis , lymphogranuloma venereum , chancroid , hepatitis B Participant condition , opinion investigator , participation would best interest participant ( example , compromise wellbeing ) could prevent , limit , confound protocolspecified assessment Participant major surgery within 4 week prior Screening plan major surgery course study Participant thyroidectomy active thyroid disease require medication last 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>adenovirus serotype 26</keyword>
	<keyword>Ad26.Mos.HIV</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Placebo</keyword>
	<keyword>Glycoprotein</keyword>
	<keyword>IPCAVD010</keyword>
</DOC>